Selected article for: "acute respiratory distress syndrome and lung mediate"
Author: Fanelli, Vito; Fiorentino, Marco; Cantaluppi, Vincenzo; Gesualdo, Loreto; Stallone, Giovanni; Ronco, Claudio; Castellano, Giuseppe
Title: Acute kidney injury in SARS-CoV-2 infected patients
  • Document date: 2020_4_16
    • ID: 0gcx16h2_1
    Snippet: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the pathogen responsible of atypical pneumonia that has affected more than 330,000 people and caused death of more than 14,000 patients (as of March 23, 2020, WHO Report). Coronavirus spike (S) glycoproteins mediate entry into cells end predominantly lung epithelial alveolar cells precipitating an interstitial pneumonia that evolves through acute respiratory distress syndrome (ARDS) .....
    Document: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the pathogen responsible of atypical pneumonia that has affected more than 330,000 people and caused death of more than 14,000 patients (as of March 23, 2020, WHO Report). Coronavirus spike (S) glycoproteins mediate entry into cells end predominantly lung epithelial alveolar cells precipitating an interstitial pneumonia that evolves through acute respiratory distress syndrome (ARDS) [1] . Interestingly, about 25% of acute kidney injury (AKI) occurrence has been reported in this clinical setting [2, 3] . These data were recently confirmed by the Italian Report of "Istituto Superiore di Sanità" describing an incidence of 27.8% in more than 2000 patients (updated on 17 March) (https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_17_marzo-v2.pdf). In this commentary, we discuss possible mechanisms of the COVID-19-induced AKI, indicating potential new approaches for risk stratification of SARS-CoV-2 infected patients that may help clinical decision in this emerging scenario.

    Search related documents:
    Co phrase search for related documents
    • acute ARDS respiratory distress syndrome and alveolar cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute ARDS respiratory distress syndrome and ARDS respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ARDS respiratory distress syndrome and atypical pneumonia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ARDS respiratory distress syndrome and clinical decision: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute ARDS respiratory distress syndrome and clinical setting: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute ARDS respiratory distress syndrome and distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ARDS respiratory distress syndrome and end cell: 1
    • acute ARDS respiratory distress syndrome and entry mediate: 1, 2
    • acute ARDS respiratory distress syndrome evolve and ARDS respiratory distress syndrome: 1, 2, 3, 4, 5
    • acute ARDS respiratory distress syndrome evolve and distress syndrome: 1, 2, 3, 4, 5
    • acute kidney injury and AKI occurrence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute kidney injury and alveolar cell: 1, 2
    • acute kidney injury and ARDS respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute kidney injury and atypical pneumonia: 1, 2, 3
    • acute kidney injury and clinical decision: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute kidney injury and clinical setting: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute kidney injury and distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute kidney injury and end cell: 1, 2
    • AKI occurrence and ARDS respiratory distress syndrome: 1, 2, 3